Partnering

Business model: licensing-out innovative products and technology platforms

Adocia business model is to develop innovative assets and establish proof-of-concept before licensing-out to pharmaceutical partners.

Over the years, Adocia has built a diversified pipeline of specialty products in diabetes and obesity. The products development stage ranges from proof of concept in animals to Phase 3 clinical trials. Adocia is actively seeking partners to continue the development of these products and to ensure their commercialization.

Adocia’s products are based on four proprietary technology platforms for which the company is exploring partnership opportunities across all therapeutic areas.

• BioChaperone^®, platform for molecular delivery of therapeutic proteins
• AdoShell^®, platform for cell therapy
• AdOral^®, platform for oral delivery of peptides
• AdoXLong^TM, long-acting injectable peptide formulation

Adocia provides the opportunity for an initial feasibility study to evaluate potential partners molecules with Adocia technology platforms. Technology platforms licensing opportunities are open for discussions within all therapeutic areas.